RKDANasdaqCrude Petroleum & Natural GasFiscal year ends December 31
Arcadia Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.14−0.02 (-12.01%)
Close on Oct 19, 2026
- Market cap
- $433.92K
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
8.8%
0M of 2M shares
Institutional holders
16
8 new, 7 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| MJL Manager LLC | 378,740 | 15.70% | 13G (passive) | Sep 25, 2026 |
| Armistice Capital, LLC | 267,392 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Steven Boyd | 159,390 | 7.75% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RKDA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 88,386 | 3.67% | $60 | New | 0.00% |
| Citadel Advisors LLC | 23,738 | 0.99% | $16.12K | New | 0.00% |
| Virtu Financial LLC | 21,786 | 0.90% | $15 | New | 0.00% |
| Geode Capital Management, LLC | 16,135 | 0.67% | $10.96K | −15,608 | 0.00% |
| XTX Topco Ltd | 15,475 | 0.64% | $10.51K | New | 0.00% |
| StoneX Group Inc. | 13,682 | 0.57% | $11.26K | New | 0.00% |
| State Street Corp | 12,146 | 0.50% | $8.25K | – | 0.00% |
| Jane Street Group, LLC | 10,245 | 0.43% | $6.96K | New | 0.00% |
| Vanguard Capital Management LLC | 9,644 | 0.40% | $6.55K | – | 0.00% |
| SBI Securities Co., Ltd. | 120 | 0.00% | $81 | – | 0.00% |
| TD Waterhouse Canada Inc. | 70 | 0.00% | $50 | New | 0.00% |
| UBS Group AG | 35 | 0.00% | $24 | −772 | 0.00% |
| Group One Trading, L.P. | 18 | 0.00% | $12 | – | 0.00% |
| Morgan Stanley | 2 | 0.00% | $1 | – | 0.00% |
| Southern Michigan Bank & Trust | 2 | 0.00% | $1 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $1 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 16 | 0M | 8.8% | 8 / 0 | 2 / 7 | 0M | 0M |
| Q1 2026 | 15 | 0M | 14.5% | 6 / 3 | 0 / 3 | 0M | 0M |
| Q4 2025 | 13 | 0M | 1.6% | 0 / 0 | 6 / 3 | 0M | 0M |
| Q3 2025 | 16 | 0M | 2.7% | 3 / 2 | 5 / 1 | 0M | 0M |
| Q2 2025 | 14 | 0M | 2.5% | 1 / 3 | 2 / 1 | 0M | 0M |
| Q1 2025 | 14 | 0M | 3.2% | 2 / 3 | 1 / 1 | 0M | 0M |
| Q4 2024 | 13 | 0M | 3.3% | 3 / 1 | 0 / 3 | 0M | 0M |
| Q3 2024 | 13 | 0M | 2.2% | 3 / 0 | 2 / 1 | 0M | 0M |
| Q2 2024 | 11 | 0M | 1.2% | 2 / 0 | 2 / 4 | 0M | 0M |
| Q1 2024 | 13 | 0M | 3.4% | 2 / 2 | 1 / 3 | 0M | 0M |
| Q4 2023 | 14 | 0M | 5.8% | 3 / 4 | 0 / 0 | 0M | 0M |
| Q3 2023 | 11 | 0M | 2.0% | 0 / 1 | 5 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RKDA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 27,879 | 1.16% | $26.90K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 9,644 | 0.40% | $6.55K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 1,716 | 0.07% | $1.66K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 1,626 | 0.07% | $1.57K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas J. Schaefer | Chief Executive Officer | 2,819 | 0.12% | May 12, 2025 |
| Mark Kawakami | Chief Financial Officer | 2,681 | 0.11% | May 12, 2025 |
| Lilian Shackelford Murray | Director | 8,524 | 0.35% | Sep 14, 2026 |
| Kevin Comcowich | Director | 20,000 | 0.83% | Sep 14, 2026 |
| Gregory D. Waller | Director | – | – | Sep 14, 2026 |
| Amy Yoder | Director | – | – | Sep 14, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark Kawakami Chief Financial Officer | Feb 3, 2025 | Buy | +700 | $2.49 | $1.74K | 2,681 |
| Thomas J. Schaefer Chief Executive Officer | Feb 3, 2025 | Buy | +700 | $2.49 | $1.74K | 2,819 |
| Mark Kawakami Chief Financial Officer | Aug 1, 2024 | Buy | +700 | $2.06 | $1.44K | 1,981 |
| Thomas J. Schaefer Chief Executive Officer | Aug 1, 2024 | Buy | +700 | $2.06 | $1.44K | 2,119 |
| Thomas J. Schaefer Chief Financial Officer | Feb 1, 2024 | Buy | +700 | $2.06 | $1.44K | 1,419 |
| Thomas J. Schaefer Chief Financial Officer | Aug 4, 2023 | Buy | +649 | $3.67 | $2.38K | 719 |
| Stanley Jacot Jr Chief Executive Officer | May 30, 2023 | Buy | +5,000 | $4.31 | $21.55K | 5,000 |
| Thomas J. Schaefer Chief Financial Officer | Feb 1, 2023 | Buy | +700 | $0.23 | $161 | 2,800 |
| Pamela Haley Chief Financial Officer | Aug 1, 2022 | Buy | +700 | $0.70 | $490 | 5,088 |
| Randall Shultz Chief Technology Officer | Aug 3, 2020 | Buy | +700 | $3.16 | $2.21K | 13,000 |
| Pamela Haley Chief Financial Officer | Aug 3, 2020 | Buy | +700 | $3.16 | $2.21K | 2,638 |
| Matthew T. Plavan Chief Executive Officer | Aug 3, 2020 | Buy | +585 | $3.16 | $1.85K | 14,285 |
| Sarah Reiter Chief Commercial Officer | Feb 3, 2020 | Buy | +700 | $1.72 | $1.20K | 3,800 |
| Matthew T. Plavan Chief Executive Officer | Feb 3, 2020 | Buy | +700 | $1.72 | $1.20K | 13,700 |
| Pamela Haley Chief Financial Officer | Feb 3, 2020 | Buy | +700 | $1.72 | $1.20K | 1,938 |
| Sarah Reiter Chief Commercial Officer | Dec 23, 2019 | Buy | +900 | $5.95 | $5.36K | 3,100 |
| Sarah Reiter Chief Commercial Officer | Nov 19, 2019 | Buy | +1,000 | $4.52 | $4.52K | 2,200 |
| Lilian Shackelford Murray Director | Nov 18, 2019 | Buy | +5,000 | $4.25 | $21.25K | 8,524 |
| Matthew T. Plavan Chief Executive Officer | Nov 14, 2019 | Buy | +1,000 | $4.08 | $4.08K | 13,000 |
| Matthew T. Plavan Chief Executive Officer | Sep 23, 2019 | Buy | +2,000 | $5.25 | $10.50K | 12,000 |
| Kevin Comcowich Director | Sep 17, 2019 | Buy | +5,000 | $5.88 | $29.40K | 20,000 |
| Matthew T. Plavan Chief Executive Officer | Sep 10, 2019 | Buy | +1,000 | $6.52 | $6.52K | 10,000 |
| Matthew T. Plavan Chief Executive Officer | Sep 10, 2019 | Buy | +1,000 | $6.49 | $6.49K | 9,000 |
| Sarah Reiter Chief Commercial Officer | Sep 10, 2019 | Buy | +1,200 | $6.48 | $7.78K | 1,200 |
| Kevin Comcowich Director | Sep 10, 2019 | Buy | +5,000 | $6.49 | $32.45K | 5,000 |
| Kevin Comcowich Director | Sep 10, 2019 | Buy | +10,000 | $6.49 | $64.90K | 15,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 28, 2019 | Award | +1,000 | $6.88 | $6.88K | 8,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 28, 2019 | Buy | +1,000 | $6.88 | $6.88K | 8,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Award | +2,000 | $8.93 | $17.86K | 7,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Award | +1,000 | $9.32 | $9.32K | 3,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Award | +1,000 | $9.30 | $9.30K | 4,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Award | +1,000 | $8.95 | $8.95K | 5,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Buy | +1,000 | $8.95 | $8.95K | 5,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Buy | +1,000 | $9.32 | $9.32K | 3,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Buy | +1,000 | $9.30 | $9.30K | 4,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Buy | +2,000 | $8.93 | $17.86K | 7,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 26, 2019 | Award | +1,000 | $8.33 | $8.33K | 1,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 26, 2019 | Award | +1,000 | $9.22 | $9.22K | 2,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 26, 2019 | Buy | +1,000 | $8.33 | $8.33K | 1,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 26, 2019 | Buy | +1,000 | $9.22 | $9.22K | 2,000 |
| Eric J. Rey Director | Mar 23, 2018 | Option exercise | +5,000 | $21.60 | $108.00K | 12,335 |
| Eric J. Rey Director | Mar 23, 2018 | Sale | −5,000 | $33.44 | $167.20K | 7,335 |
| Zhongjin Lu VP Product Development | Mar 23, 2018 | Sale | −1,750 | $32.74 | $57.30K | 558 |
| Zhongjin Lu VP Product Development | Mar 23, 2018 | Option exercise | +1,750 | $21.60 | $37.80K | 2,308 |
| Eric J. Rey Director | Mar 15, 2018 | Option exercise | +250 | $44.80 | $11.20K | 7,585 |
| Eric J. Rey Director | Mar 15, 2018 | Sale(10b5-1 plan) | −250 | $60.00 | $15.00K | 7,335 |
| Eric J. Rey Director | Mar 14, 2018 | Sale(10b5-1 plan) | −21,005 | $45.21 | $949.64K | 7,335 |
| Eric J. Rey Director | Mar 14, 2018 | Option exercise | +21,005 | $21.60 | $453.71K | 28,340 |
| Zhongjin Lu VP Product Development | Nov 17, 2017 | Sale | −5,950 | $0.23 | $1.37K | 11,153 |
| Eric J. Rey Director | Jun 8, 2017 | Buy | +5,000 | $0.75 | $3.75K | 146,680 |
| Roger Salameh Chief Operating Officer | Aug 4, 2016 | Sale(10b5-1 plan) | −100 | $2.51 | $251 | 11,415 |
| Roger Salameh Chief Operating Officer | Aug 4, 2016 | Option exercise | +100 | $1.08 | $108 | 11,515 |
| Steven F. Brandwein Interim Chief Financ. Officer | Jun 13, 2016 | Sale(10b5-1 plan) | −8,280 | $2.49 | $20.62K | 750 |
| Steven F. Brandwein Interim Chief Financ. Officer | Apr 25, 2016 | Sale(10b5-1 plan) | −1,720 | $2.42 | $4.16K | 9,030 |
| Vic C. Knauf Chief Scientific Officer, Director | Apr 5, 2016 | Sale(10b5-1 plan) | −1,653 | $2.98 | $4.93K | 47,134 |
| Vic C. Knauf Chief Scientific Officer, Director | Apr 5, 2016 | Option exercise | +1,653 | $1.08 | $1.79K | 48,787 |
| Vic C. Knauf Chief Scientific Officer, Director | Apr 4, 2016 | Option exercise | +1,200 | $1.08 | $1.30K | 48,334 |
| Vic C. Knauf Chief Scientific Officer, Director | Apr 4, 2016 | Sale(10b5-1 plan) | −1,200 | $2.98 | $3.58K | 47,134 |
| Vic C. Knauf Chief Scientific Officer, Director | Mar 4, 2016 | Option exercise | +2,973 | $1.08 | $3.21K | 50,107 |
| Vic C. Knauf Chief Scientific Officer, Director | Mar 4, 2016 | Sale(10b5-1 plan) | −2,973 | $3.22 | $9.57K | 47,134 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.